(Q45417551)

14 December 2017

Transcutaneous vaccination with virus-like particles (English)

1 reference

14 December 2017

1

Sarah L Young

1 reference

14 December 2017

Michelle Wilson

2

1 reference

14 December 2017

Sarah Wilson

3

1 reference

14 December 2017

Kenneth W Beagley

4

1 reference

14 December 2017

Vernon Ward

5

1 reference

14 December 2017

Margaret A Baird

6

1 reference

14 December 2017

language of work or name

English

0 references

publication date

30 March 2006

1 reference

14 December 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

14 December 2017

24

1 reference

14 December 2017

26

1 reference

14 December 2017

5406-5412

1 reference

Danish bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children.

14 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Bystander help within a polyepitope DNA vaccine improves immune responses to influenza antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

The virosome concept for influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Virus-like particles of calicivirus as epitope carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Gene transfer using recombinant rabbit hemorrhagic disease virus capsids with genetically modified DNA encapsidation capacity by addition of packaging sequences from the L1 or L2 protein of human papillomavirus type 16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Translating cell biology in vitro to immunity in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

A Toll-like receptor recognizes bacterial DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Modulation of immune responses with transcutaneously deliverable adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Induction of anti-chlamydial mucosal immunity by transcutaneous immunization is enhanced by topical application of GM-CSF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Cellular immunity and Chlamydia genital infection: induction, recruitment, and effector mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Chlamydia trachomatis infection: incidence, health costs and prospects for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Macrophages, CD4+ or CD8+ cells are each sufficient for protection against Chlamydia pneumoniae infection through their ability to secrete IFN-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

Virus-like particle vaccines for mucosal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.052

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.03.052

1 reference

14 December 2017

1 reference